Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

L. M. Smith, J. R. Anderson, S. J. Qualman, W. M. Crist, C. N. Paidas, L. A. Teot, A. S. Pappo, M. P. Link, H. E. Grier, E. S. Wiener, J. C. Breneman, R. B. Raney, H. M. Maurer, S. S. Donaldson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: To identify which patients with rhabdomyosarcoma and microscopic residual disease (group II) are likely to not respond to therapy. Patients and Methods: Six hundred ninety-five patients with group II tumors received chemotherapy and 90% received radiation therapy on Intergroup Rhabdomyosarcoma Study (IRS)-I to IRS-IV (1972 to 1997). Tumors were subgrouped depending on the presence of microscopic residual disease only (subgroup Ila), resected positive regional lymph nodes, (subgroup IIb), or microscopic residual disease and resected positive regional lymph nodes (subgroup IIc). Results: Overall, the 5-year failure-free survival rate (FFSR) was 73%, and patients with embryonal rhabdomyosarcoma treated on IRS-IV fared especially well (5-year FFSR, 93%; n = 90). Five-year FFSRs differed significantly by subgroup (IIa, 75% and n = 506; IIb, 74% and n = 101; IIc, 58% and n = 88; P = .0037) and treatment (IRS-I, 68%; IRS-II, 67%; IRS-III, 75%; IRS-IV, 87%; P < .001). Multivariate analysis revealed positive associations between primary site (favorable), histology (embryonal), subgroup IIa or IIb, treatment (IRS-III/IV), and better FFSRs. Patterns of treatment failure revealed local failure to be 8%, regional failure, 4%, and distant failure, 14%. The relapse pattern noted over the course of IRS-I to IRS-IV shows a decrease in the systemic relapse rates, particularly for patients with embryonal histology, suggesting that improvement in FFSRs is primarily a result of improved chemotherapy. Conclusion: Group II rhabdomyosarcoma has an excellent prognosis with contemporary therapy as used in IRS-III/IV, and those less likely to respond can be identified using prognostic factors: histology, subgroup, and primary site. Patients with embryonal rhabdomyosarcoma are generally cured, although patients with alveolar rhabdomyosarcoma or undifferentiated sarcoma, particularly subgroup IIc at unfavorable sites, continue to need better therapy.

Original languageEnglish (US)
Pages (from-to)4058-4064
Number of pages7
JournalJournal of Clinical Oncology
Volume19
Issue number20
DOIs
StatePublished - Oct 15 2001

Fingerprint

Rhabdomyosarcoma
Sarcoma
Recurrence
Therapeutics
Embryonal Rhabdomyosarcoma
Histology
Survival Rate
Lymph Nodes
Alveolar Rhabdomyosarcoma
Drug Therapy
Treatment Failure
Neoplasms
Radiotherapy
Multivariate Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. / Smith, L. M.; Anderson, J. R.; Qualman, S. J.; Crist, W. M.; Paidas, C. N.; Teot, L. A.; Pappo, A. S.; Link, M. P.; Grier, H. E.; Wiener, E. S.; Breneman, J. C.; Raney, R. B.; Maurer, H. M.; Donaldson, S. S.

In: Journal of Clinical Oncology, Vol. 19, No. 20, 15.10.2001, p. 4058-4064.

Research output: Contribution to journalArticle

Smith, LM, Anderson, JR, Qualman, SJ, Crist, WM, Paidas, CN, Teot, LA, Pappo, AS, Link, MP, Grier, HE, Wiener, ES, Breneman, JC, Raney, RB, Maurer, HM & Donaldson, SS 2001, 'Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group', Journal of Clinical Oncology, vol. 19, no. 20, pp. 4058-4064. https://doi.org/10.1200/JCO.2001.19.20.4058
Smith, L. M. ; Anderson, J. R. ; Qualman, S. J. ; Crist, W. M. ; Paidas, C. N. ; Teot, L. A. ; Pappo, A. S. ; Link, M. P. ; Grier, H. E. ; Wiener, E. S. ; Breneman, J. C. ; Raney, R. B. ; Maurer, H. M. ; Donaldson, S. S. / Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 20. pp. 4058-4064.
@article{5d1eb4b90aed40379337f66c9792eafb,
title = "Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group",
abstract = "Purpose: To identify which patients with rhabdomyosarcoma and microscopic residual disease (group II) are likely to not respond to therapy. Patients and Methods: Six hundred ninety-five patients with group II tumors received chemotherapy and 90{\%} received radiation therapy on Intergroup Rhabdomyosarcoma Study (IRS)-I to IRS-IV (1972 to 1997). Tumors were subgrouped depending on the presence of microscopic residual disease only (subgroup Ila), resected positive regional lymph nodes, (subgroup IIb), or microscopic residual disease and resected positive regional lymph nodes (subgroup IIc). Results: Overall, the 5-year failure-free survival rate (FFSR) was 73{\%}, and patients with embryonal rhabdomyosarcoma treated on IRS-IV fared especially well (5-year FFSR, 93{\%}; n = 90). Five-year FFSRs differed significantly by subgroup (IIa, 75{\%} and n = 506; IIb, 74{\%} and n = 101; IIc, 58{\%} and n = 88; P = .0037) and treatment (IRS-I, 68{\%}; IRS-II, 67{\%}; IRS-III, 75{\%}; IRS-IV, 87{\%}; P < .001). Multivariate analysis revealed positive associations between primary site (favorable), histology (embryonal), subgroup IIa or IIb, treatment (IRS-III/IV), and better FFSRs. Patterns of treatment failure revealed local failure to be 8{\%}, regional failure, 4{\%}, and distant failure, 14{\%}. The relapse pattern noted over the course of IRS-I to IRS-IV shows a decrease in the systemic relapse rates, particularly for patients with embryonal histology, suggesting that improvement in FFSRs is primarily a result of improved chemotherapy. Conclusion: Group II rhabdomyosarcoma has an excellent prognosis with contemporary therapy as used in IRS-III/IV, and those less likely to respond can be identified using prognostic factors: histology, subgroup, and primary site. Patients with embryonal rhabdomyosarcoma are generally cured, although patients with alveolar rhabdomyosarcoma or undifferentiated sarcoma, particularly subgroup IIc at unfavorable sites, continue to need better therapy.",
author = "Smith, {L. M.} and Anderson, {J. R.} and Qualman, {S. J.} and Crist, {W. M.} and Paidas, {C. N.} and Teot, {L. A.} and Pappo, {A. S.} and Link, {M. P.} and Grier, {H. E.} and Wiener, {E. S.} and Breneman, {J. C.} and Raney, {R. B.} and Maurer, {H. M.} and Donaldson, {S. S.}",
year = "2001",
month = "10",
day = "15",
doi = "10.1200/JCO.2001.19.20.4058",
language = "English (US)",
volume = "19",
pages = "4058--4064",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

AU - Smith, L. M.

AU - Anderson, J. R.

AU - Qualman, S. J.

AU - Crist, W. M.

AU - Paidas, C. N.

AU - Teot, L. A.

AU - Pappo, A. S.

AU - Link, M. P.

AU - Grier, H. E.

AU - Wiener, E. S.

AU - Breneman, J. C.

AU - Raney, R. B.

AU - Maurer, H. M.

AU - Donaldson, S. S.

PY - 2001/10/15

Y1 - 2001/10/15

N2 - Purpose: To identify which patients with rhabdomyosarcoma and microscopic residual disease (group II) are likely to not respond to therapy. Patients and Methods: Six hundred ninety-five patients with group II tumors received chemotherapy and 90% received radiation therapy on Intergroup Rhabdomyosarcoma Study (IRS)-I to IRS-IV (1972 to 1997). Tumors were subgrouped depending on the presence of microscopic residual disease only (subgroup Ila), resected positive regional lymph nodes, (subgroup IIb), or microscopic residual disease and resected positive regional lymph nodes (subgroup IIc). Results: Overall, the 5-year failure-free survival rate (FFSR) was 73%, and patients with embryonal rhabdomyosarcoma treated on IRS-IV fared especially well (5-year FFSR, 93%; n = 90). Five-year FFSRs differed significantly by subgroup (IIa, 75% and n = 506; IIb, 74% and n = 101; IIc, 58% and n = 88; P = .0037) and treatment (IRS-I, 68%; IRS-II, 67%; IRS-III, 75%; IRS-IV, 87%; P < .001). Multivariate analysis revealed positive associations between primary site (favorable), histology (embryonal), subgroup IIa or IIb, treatment (IRS-III/IV), and better FFSRs. Patterns of treatment failure revealed local failure to be 8%, regional failure, 4%, and distant failure, 14%. The relapse pattern noted over the course of IRS-I to IRS-IV shows a decrease in the systemic relapse rates, particularly for patients with embryonal histology, suggesting that improvement in FFSRs is primarily a result of improved chemotherapy. Conclusion: Group II rhabdomyosarcoma has an excellent prognosis with contemporary therapy as used in IRS-III/IV, and those less likely to respond can be identified using prognostic factors: histology, subgroup, and primary site. Patients with embryonal rhabdomyosarcoma are generally cured, although patients with alveolar rhabdomyosarcoma or undifferentiated sarcoma, particularly subgroup IIc at unfavorable sites, continue to need better therapy.

AB - Purpose: To identify which patients with rhabdomyosarcoma and microscopic residual disease (group II) are likely to not respond to therapy. Patients and Methods: Six hundred ninety-five patients with group II tumors received chemotherapy and 90% received radiation therapy on Intergroup Rhabdomyosarcoma Study (IRS)-I to IRS-IV (1972 to 1997). Tumors were subgrouped depending on the presence of microscopic residual disease only (subgroup Ila), resected positive regional lymph nodes, (subgroup IIb), or microscopic residual disease and resected positive regional lymph nodes (subgroup IIc). Results: Overall, the 5-year failure-free survival rate (FFSR) was 73%, and patients with embryonal rhabdomyosarcoma treated on IRS-IV fared especially well (5-year FFSR, 93%; n = 90). Five-year FFSRs differed significantly by subgroup (IIa, 75% and n = 506; IIb, 74% and n = 101; IIc, 58% and n = 88; P = .0037) and treatment (IRS-I, 68%; IRS-II, 67%; IRS-III, 75%; IRS-IV, 87%; P < .001). Multivariate analysis revealed positive associations between primary site (favorable), histology (embryonal), subgroup IIa or IIb, treatment (IRS-III/IV), and better FFSRs. Patterns of treatment failure revealed local failure to be 8%, regional failure, 4%, and distant failure, 14%. The relapse pattern noted over the course of IRS-I to IRS-IV shows a decrease in the systemic relapse rates, particularly for patients with embryonal histology, suggesting that improvement in FFSRs is primarily a result of improved chemotherapy. Conclusion: Group II rhabdomyosarcoma has an excellent prognosis with contemporary therapy as used in IRS-III/IV, and those less likely to respond can be identified using prognostic factors: histology, subgroup, and primary site. Patients with embryonal rhabdomyosarcoma are generally cured, although patients with alveolar rhabdomyosarcoma or undifferentiated sarcoma, particularly subgroup IIc at unfavorable sites, continue to need better therapy.

UR - http://www.scopus.com/inward/record.url?scp=0035886962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035886962&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.20.4058

DO - 10.1200/JCO.2001.19.20.4058

M3 - Article

C2 - 11600608

AN - SCOPUS:0035886962

VL - 19

SP - 4058

EP - 4064

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -